Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on metformin monotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Twice-a-week dose of 1.5 mg CJC-1134-PC |
|
| 2 | Experimental | Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo |
|
| 3 | Placebo Comparator | Twice-a-week placebo for CJC-1134-PC |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 1.5 mg or 2.0 mg CJC-1134-PC | Drug | twice-a-week |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of HbA1c From Baseline | Change from baseline | Screening and Day 85 |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction in Fasting Plasma Glucose From Baseline | Change from baseline | Screening and Day 85 |
| Reduction in Fasting Body Weight From Baseline | Change from baseline |
Not provided
Major Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maggie Wang, MD | ConjuChem Biotechnologies Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maggie Wang | Montreal | Quebec | H2X 3Y8 | Canada |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 1.5 mg CJC-1134-PC | Twice-a-week dose of 1.5 mg CJC-1134-PC 1.5 mg CJC-1134-PC: twice-a-week |
| FG001 | 1.5 mg or 2.0 mg CJC-1134-PC | Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo 1.5 mg or 2.0 mg CJC-1134-PC: twice-a-week |
| FG002 | Placebo | Twice-a-week placebo for CJC-1134-PC Placebo: twice-a-week |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Safety Population
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 1.5 mg CJC-1134-PC | Twice-a-week dose of 1.5 mg CJC-1134-PC 1.5 mg CJC-1134-PC: twice-a-week |
| BG001 | 1.5 mg or 2.0 mg CJC-1134-PC | Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo 1.5 mg or 2.0 mg CJC-1134-PC: twice-a-week |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Reduction of HbA1c From Baseline | Change from baseline | Modified Intent-to-Treat Population | Posted | Mean | Standard Deviation | Percent (%) | Screening and Day 85 |
|
16 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 1.5 mg CJC-1134-PC | Twice-a-week dose of 1.5 mg CJC-1134-PC 1.5 mg CJC-1134-PC: twice-a-week |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation | Cardiac disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Associate Director of Regulatory Affairs | ConjuChem Biotechnologies Inc. | 310-405-7549 | Aleece.Nolasco@nantbio.com |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
twice-a-week |
|
| Screening and Day 85 |
| BG002 | Placebo | Twice-a-week placebo for CJC-1134-PC Placebo: twice-a-week |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Placebo |
Twice-a-week placebo for CJC-1134-PC Placebo: twice-a-week |
|
|
| Secondary | Reduction in Fasting Plasma Glucose From Baseline | Change from baseline | Modified Intent-to-Treat Population | Posted | Mean | Standard Deviation | mg/dL | Screening and Day 85 |
|
|
|
| Secondary | Reduction in Fasting Body Weight From Baseline | Change from baseline | Modified Intent-to-Treat Population | Posted | Mean | Standard Deviation | kg | Screening and Day 85 |
|
|
|
| 0 |
| 30 |
| 1 |
| 30 |
| 18 |
| 30 |
| EG001 | 1.5 mg or 2.0 mg CJC-1134-PC | Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo 1.5 mg or 2.0 mg CJC-1134-PC: twice-a-week | 0 | 30 | 0 | 30 | 19 | 30 |
| EG002 | Placebo | Twice-a-week placebo for CJC-1134-PC Placebo: twice-a-week | 0 | 29 | 1 | 29 | 20 | 29 |
| Eye infection staphylococcal | Infections and infestations | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Gastroesophageal reflux disease | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment |
|
| Toothache | Gastrointestinal disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Dizziness | Nervous system disorders | Systematic Assessment |
|
| Injection site reaction | General disorders | Systematic Assessment |
|
| Fatigue | General disorders | Systematic Assessment |
|
| Edema peripheral | General disorders | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | Systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Skin laceration | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Muscle spasms | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Sinus congestion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
Not provided
Not provided
| D004700 | Endocrine System Diseases |